BioNTech SE is expected to report Q4 2025 revenue of approximately €816.04 million and a loss per share of $0.47, with its current $101.50 stock price trading well below the $139.17 consensus price target.
Investors are primarily focused on the company's "oncology-first" pivot and the clinical progress of its Phase 3 pipeline, particularly updates regarding its bispecific antibody BNT327. Following the sharp decline in COVID-19 vaccine demand, the company is aggressively deploying its €17 billion cash reserve into research and development to diversify its revenue streams.
Analysts are seeking clarity on the 2026 commercialization path for its lead mRNA cancer immunotherapies and updated guidance on total research expenditure.